Surgicel® & Endometrial Ablation in the Management of Perimenpausal Heavy Menstrual Bleeding
Primary Purpose
Endometrial Hyperplasia
Status
Unknown status
Phase
Phase 2
Locations
Egypt
Study Type
Interventional
Intervention
SURGICEL®
Sponsored by
About this trial
This is an interventional treatment trial for Endometrial Hyperplasia focused on measuring ablation, surgicel
Eligibility Criteria
Inclusion Criteria:
- Heavy menstrual bleeding (i.e. pictorial blood loss assessment chart score >150) that unresponsive to hormonal lines of treatment & requesting conservative surgical approach.
- Uterine length <12 cm.
- FSH level > 40 IU/L
- Normal Pap smear
- Benign endometrial pathology
Exclusion Criteria:
- Active form of PID
- Uterine scars & uterine malformation.
- Uterine organic lesions (e.g., fibroids, polyps & Adenomyosis)
- Previous history of endometrial ablation.
- Patients seeking fertility preservation.
- Patients suffering coagulopathies or receiving anticoagulant treatments
Sites / Locations
- kasr elaini hospital (Cairo university)Recruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Active Comparator
No Intervention
No Intervention
Arm Label
Surgicel group
Thermal balloon ablation group
Endometrial resection group
Arm Description
80 patients underwent formal curettage followed by insertion of 4 pieces of Surgicel inside the uterine cavity
80 patients underwent thermal balloon ablation using bipolar radiofrequency electrical energy (Novasure)
80 patients underwent transcervical Hysteroscopic endometrial resection
Outcomes
Primary Outcome Measures
amenorrhea rates
absence of menstruation
Secondary Outcome Measures
PBAC score (pictorial blood loss assessment chart score)
chart consists of a series of diagrams representing lightly, moderately and heavily soiled towels and tampons.The participants complete the chart each menstrual period after clear instructions and explanation of how it should be used
dysmenorrhea rates
occurrence of painful menstruation
patient satisfaction
simple questions about decreasing duration & amount of menstrual blood & better quality of life
the need for re-intervention
hysterectomy
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03176992
Brief Title
Surgicel® & Endometrial Ablation in the Management of Perimenpausal Heavy Menstrual Bleeding
Official Title
Surgicel® Versus Endometrial Ablation in the Management of Perimenpausal Heavy Menstrual Bleeding (HMB): Randomised Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
June 2017
Overall Recruitment Status
Unknown status
Study Start Date
June 2015 (Actual)
Primary Completion Date
December 2017 (Anticipated)
Study Completion Date
February 2018 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Cairo University
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Two hundred & forty patients aged from 40 to 50 years - complaining of heavy menstrual bleeding that is unresponsive to hormonal lines of treatment & requesting conservative surgical approach- were randomized into 3 groups; group A (Surgicel group) in which 80 patients underwent formal curettage followed by insertion of 4 pieces of Surgicel inside the uterine cavity, group B (Thermal balloon ablation group) in which 80 patients underwent thermal balloon ablation using bipolar radiofrequency electrical energy (Novasure), group C (Endometrial resection group) in which 80 patients underwent transcervical Hysteroscopic endometrial resection.All patients were followed up over duration of 18 months following the procedure (at 3,6,12 & 18 months). Primary outcome included amenorrhea rates
Detailed Description
Two hundred & forty patients aged from 40 to 50 years complaining of heavy menstrual bleeding (i.e. pictorial blood loss assessment chart score >150) that is unresponsive to hormonal lines of treatment & requesting conservative surgical approach. Participants were randomized into 3 groups; group A (Surgicel group) in which 80 patients underwent formal curettage followed by insertion of 4 pieces of Surgicel inside the uterine cavity, group B (Thermal balloon ablation group) in which 80 patients underwent thermal balloon ablation using bipolar radiofrequency electrical energy (Novasure), group C (Endometrial resection group) in which 80 patients underwent transcervical Hysteroscopic endometrial resection. Randomization was done using computer generated random numbers.
Inclusion criteria included uterine length <12 cm, FSH level > 40 IU/L, normal Pap smear & benign endometrial pathology. Exclusion criteria included active form of PID, uterine scars, uterine malformation, uterine organic lesions (e.g., fibroids, polyps & Adenomyosis) & previous history of endometrial ablation. In addition, patients seeking fertility preservation, suffering coagulopathies or receiving anticoagulant treatments were excluded.
For all patients, full history was taken followed by complete physical examination (with emphasis on speculum examination to exclude cervical or vaginal wall lesions) & laboratory investigations (FSH, coagulation profile & routine preoperative investigations). History of Pap smear schedule was obtained and a Pap smear was scheduled if it was due. Transvaginal ultrasound (TVUS) was done using a 7.5 MHz vaginal probe of the General Electric Voluson E8 ultrasound unit (GE Healthcare Austria GmbH, Seoul, Korea) to assess uterine size and to exclude organic lesions of the uterus or ovaries. All participants were subjected to an endometrial biopsy (either before the procedure or intraoperatively followed by a frozen section). Patients, who were found to have atypical endometrial hyperplasia or endometrial malignancy, were excluded from the study.
In the Surgicel group (group A), each SURGICEL® (oxidized regenerated cellulose - Ethicon US, LLC.) knitted fabric (5 x 10 cm) was divided into four equal pieces. A formal cervical dilatation & curettage was done followed by packing the uterine cavity with the four SURGICEL® strips to ensure that the SURGICEL® is in contact with the basal endometrium all over the cavity.
In group B, Thermal balloon ablation was done using bipolar radiofrequency electrical energy (Novasure). The cervix was grasped with a tenaculum then dilated to 6 mm. The disposable device was inserted in the uterine cavity until the distal end of the sheath touches the fundus then withdrawn backwards approximately 0.5 cm. The cervical collar was slided forward until it forms a seal against the external cervical os. The ablation cycle starts automatically, upon successful completion of the cavity integrity assessment (CIA), & ends automatically as well. In group C, Transcervical hysteroscopic endometrial resection was done. Bipolar resectoscope is used & endometrium is resected in successive passes under direct hysteroscopic vision. Each pass of the U-shaped loop electrode removes a layer of tissue of approximately 3-5 mm.
All patients were followed up over duration of 18 months following the procedure (at 3,6,12 & 18 months). Primary outcome included amenorrhea rates & secondary outcomes included complication (intra- or post-operative), PBAC score (pictorial blood loss assessment chart score), dysmenorrhea rates, patient satisfaction & the need for re-intervention (hysterectomy).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Endometrial Hyperplasia
Keywords
ablation, surgicel
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Allocation
Randomized
Enrollment
240 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Surgicel group
Arm Type
Active Comparator
Arm Description
80 patients underwent formal curettage followed by insertion of 4 pieces of Surgicel inside the uterine cavity
Arm Title
Thermal balloon ablation group
Arm Type
No Intervention
Arm Description
80 patients underwent thermal balloon ablation using bipolar radiofrequency electrical energy (Novasure)
Arm Title
Endometrial resection group
Arm Type
No Intervention
Arm Description
80 patients underwent transcervical Hysteroscopic endometrial resection
Intervention Type
Drug
Intervention Name(s)
SURGICEL®
Intervention Description
insertion of 4 pieces of Surgicel inside the uterine cavity after formal curettage
Primary Outcome Measure Information:
Title
amenorrhea rates
Description
absence of menstruation
Time Frame
18 months
Secondary Outcome Measure Information:
Title
PBAC score (pictorial blood loss assessment chart score)
Description
chart consists of a series of diagrams representing lightly, moderately and heavily soiled towels and tampons.The participants complete the chart each menstrual period after clear instructions and explanation of how it should be used
Time Frame
18 months
Title
dysmenorrhea rates
Description
occurrence of painful menstruation
Time Frame
18 months
Title
patient satisfaction
Description
simple questions about decreasing duration & amount of menstrual blood & better quality of life
Time Frame
18 months
Title
the need for re-intervention
Description
hysterectomy
Time Frame
18 months
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Heavy menstrual bleeding (i.e. pictorial blood loss assessment chart score >150) that unresponsive to hormonal lines of treatment & requesting conservative surgical approach.
Uterine length <12 cm.
FSH level > 40 IU/L
Normal Pap smear
Benign endometrial pathology
Exclusion Criteria:
Active form of PID
Uterine scars & uterine malformation.
Uterine organic lesions (e.g., fibroids, polyps & Adenomyosis)
Previous history of endometrial ablation.
Patients seeking fertility preservation.
Patients suffering coagulopathies or receiving anticoagulant treatments
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
MOUTAZ ELSHERBINI, MD
Phone
(+20)01001588300
Email
mizosherbini@yahoo.com
First Name & Middle Initial & Last Name or Official Title & Degree
FADEL SHALTOUT, MD
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
MOUTAZ ELSHERBINI, MD
Organizational Affiliation
Assistant professor of obstetrics and gynecology
Official's Role
Principal Investigator
Facility Information:
Facility Name
kasr elaini hospital (Cairo university)
City
Cairo
ZIP/Postal Code
115431
Country
Egypt
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
MOUTAZ ELSHERBINI, MD
Phone
(+2)01001588300
Email
mizosherbini@yahoo.com
First Name & Middle Initial & Last Name & Degree
MOUTAZ ELSHERBINI, md
12. IPD Sharing Statement
Learn more about this trial
Surgicel® & Endometrial Ablation in the Management of Perimenpausal Heavy Menstrual Bleeding
We'll reach out to this number within 24 hrs